Update: Visitect and Allersys progress rapidly
Omega’s development update on 1 June reported that the Visitect CD4 test for HIV monitoring has completed its pilot validation. The next stage is manufacturing batch testing before further field trials; Omega is manufacturing in-house using new specialist facilities. The Allersys range (Allergy iSYS) now has 32 optimised allergen tests (up from 27 in March) of which 22 have full claim support; 40 are targeted for launch. Manufacturing has been validated and 27 tests produced. Testing will be in June and July.Omega Diagnostics Group is a holding company. Through its subsidiaries, Co. is engaged in the manufacturing, development and distribution of medical diagnostics products. Co. has three operating divisions: Allergy and autoimmune, which in the research, development, production and marketing of in-vitro allergy and autoimmune tests; Food intolerance, which provides clinical analysis to the general public, clinics and health professionals as well as supplying the consumer; and Infectious disease and Other, which comprise of research, development, production and marketing of kits to aid the diagnosis of infectious diseases.
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.